I have seen something similar before.....this was premarket a couple weeks back going to 1.15 or up 12%........when market opened it was at 1.01......so don't raise ur hopes. But you never know until the opening bell.
The only hope I have is for increasing interest in the stock.
Other than incremental interesting results from the skeletal mucsle programs or preclinical hypertension data or something of that nature, there is no data until the ATOMIC results in July or August. Also, I don't expect a partnership to be announced. At this point I don't think Cytokinetics intends to partner; why encumber an asset when major clinical results are expected with a second asset that may lead the only current partner to want to buy the whole company. I think once the Phase2b Omecamtiv Mecarbil trial progressed to a certain point, the closer they've gotten to having results, the less interested Cytokinetics has been in partnering Tirasemtiv. So if a buyout is in the cards, I don't expect one yet. But if the Phase 2 heart failure results are strong (with a resulting increase in share price) Amgen may be willing to pay a premium that results in a price acceptable to Cytokinetics. So at most any pop in price would likely only be due to interested parties getting in or adding to a position, rather than hinting at some imminent event.